Deciphering Therapeutic Targeting of Cathepsin B Using Repurposed Drug Darifenacin
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500117 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Sayantani Mukhopadhyay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati 39, Assam, 781039, India. Hauptthemen laut MEDLINE: Cathepsin B, Antineoplastic Agents, Drug Repositioning, Benzofurans. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Indian Council of Medical Research, Department of Electronics and Information Technology, Ministry of Communications and Information Technology.
Abstract (Originalsprache)
Cathepsins are lysosomal proteases with well‐documented roles in the progression of various cancers. Among them, cathepsin B (CTSB), a cysteine protease, is notably involved in the development of breast cancer and neuroblastoma. This article, explores the potential of darifenacin as a repurposed therapeutic targeting CTSB, using molecular docking and simulation studies which demonstrate a significantly lower binding energy against CTSB (−456.268 kJ mol −1 ) compared to its known inhibitor, aloxistatin (−36.601 kJ mol −1 ). The cytotoxic efficacy of darifenacin is evaluated on IMR‐32 (neuroblastoma) and MCF‐7 (breast cancer) cells, yielding half‐maximal inhibitory concentrations (IC50) of 38.14 and 39.96 μM, respectively. Darifenacin effectively inhibits CTSB enzymatic activity by ≈1.82‐fold and ≈1.75‐fold in IMR‐32 and MCF‐7 cells, respectively, triggering intracellular reactive oxygen species generation, mitochondrial membrane potential depolarization, and cell cycle arrest. These events culminates in apoptosis‐mediated cell death, with apoptotic populations reaching 51.39% in IMR‐32 and 40.6% in MCF‐7 cells, respectively. Additionally, darifenacin disrupts lipid droplet accumulation, cellular migration, and colony‐ and sphere‐forming abilities in both cell lines. Overall, this article identifies darifenacin as a promising therapeutic agent against CTSB‐driven cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati 39, Assam, 781039, India.
- Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati 39, Assam, 781039, India.
- Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 39, Assam, 781039, India.
ORCID-Profile: Sayantani Mukhopadhyay, Thirukumaran Kandasamy, Parameswar Krishnan Iyer, Siddhartha Sankar Ghosh
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Indian Council of Medical Research
- Department of Electronics and Information Technology, Ministry of Communications and Information Technology
Zitieren
APA
Mukhopadhyay, S., Kandasamy, T., Iyer, P. K., & Ghosh, S. S. (2025). Deciphering Therapeutic Targeting of Cathepsin B Using Repurposed Drug Darifenacin. ChemMedChem. https://doi.org/10.1002/cmdc.202500117
Vancouver
Mukhopadhyay S, Kandasamy T, Iyer PK, Ghosh SS. Deciphering Therapeutic Targeting of Cathepsin B Using Repurposed Drug Darifenacin. ChemMedChem. 2025. doi:10.1002/cmdc.202500117
BibTeX
@article{Mukhopadhyay2025,
author = {Mukhopadhyay, Sayantani and Kandasamy, Thirukumaran and Iyer, Parameswar Krishnan and Ghosh, Siddhartha Sankar},
title = {Deciphering Therapeutic Targeting of Cathepsin B Using Repurposed Drug Darifenacin},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500117}
}
EUVIMED